In addition, RCC-EVs were studied for their modulation of vascular permeability affecting metastatization, thanks to their enrichment in the azurocidin protein (AZU1) being significantly higher in serum and cancer-tissue-derived EVs from ccRCC patients compared to those from healthy donors. This evidence concerns the gene AZU1 and renal cell carcinoma.